Lung Cancer

Personalizing Immunotherapy in NSCLC Using PD-L1 and Tumor Mutation Burden as Biomarkers

Wayne Kuznar

April 2019, Vol 10, No 2 - Immunotherapy, Lung Cancer

San Francisco, CA—Tumor expression of PD-L1 has consistently predicted ­response and survival outcomes in non–small-cell lung cancer (NSCLC), whereas the role of PD-L1 in immune cells is unclear, said Edward B. Garon, MD, Director, Thoracic Oncology Program, David Geffen School of Medicine, University of California, Los Angeles, at the 2019 ASCO-SITC Clinical Immuno-Oncology Symposium. [ Read More ]

Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation

Lisa A. Raedler, PhD, RPh

2018 Third Annual Oncology Guide to New FDA Approvals - FDA Approvals, News & Updates, Lung Cancer

Lung cancer is one of the most common cancers in men and women, and is the leading cause of cancer-related mortality in the United States. According to the American Cancer Society, more than 155,000 Americans will die from lung cancer in 2017, representing approximately 25% of all cancer deaths. Non–small-cell lung cancer (NSCLC), the most common form of the disease, accounts for 80% to 85% of all lung cancer cases. [ Read More ]

When Does Immunotherapy Work Best in Lung Cancer?

Wayne Kuznar

Immunotherapy, Lung Cancer

Chicago, IL—Response to immunotherapy in non–small-cell lung cancer (NSCLC) differs depending on the driver mutation involved and on the amount of PD-L1 expression within the tumor. Immune checkpoint inhibitors in NSCLC—PD-1 and PD-L1 inhibitors—have similar efficacy and adverse event profiles. These were among the topics discussed at the 2017 ASCO annual meeting in a session on immunotherapy and lung cancer. [ Read More ]